Skip to main content

Market Overview

Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday

Share:
Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V. (NASDAQ: PRQR) and Evofem Biosciences, Inc. (NASDAQ: EVFM) are among the biggest health care movers Thursday.

Cellect to Merge With Quoin: Cellect, which provides biotech companies with the technology to select stem cells to be used in cell-therapy research, announced a merger deal with privately held Quoin Pharmaceuticals.

The deal will leave Cellect shareholders owning 25% of the combined company and Quoin owning the remainder stake.

Cellect also announced the signing of a deal to divest the entire stake in its Cellect Biotherapeutics subsidiary in favor of EnCellX Inc.

Cellect shares were rallying 40.11% to $4.89.

Immutep, F-star Gain On Positive News On Rival's Candidate: Immutep, an Australian biotech that develops immunotherapies for cancer and autoimmune disorders, and U.K.-based F-star, a clinical-stage biopharma developing tetravalent bispecific antibodies for cancer treatment, are reacting to a positive readout from Bristol-Myers Squibb (NYSE: BMY).

The large-cap biopharma announced positive primary results from the Phase 2/3 trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma.

Both Immutep and F-star are developing anti-LAG-3 antibody treatments.

Immutep stock was gaining 32.32% to $3.48.

Related Link: The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal

ProQR Finds Follow-through Buying: ProQR reported Wednesday positive data from a Phase 1/2 study evaluating QR-421a as a treatment for Usher syndrome type 2. The stock ended the session up 5.2% at $5.68.

Sell-side firms Chardan and H.C. Wainwright issued positive commentary on the biopharma in their review of data.

F-star was advancing 26.96% to $4.60.

Evofem Slides On Follow-on Offering: Evofem, a commercial-stage biopharma focusing on women's sexual and reproductive health, priced its underwritten public offering of 17.143 million shares of its common stock at a price to the public of $1.75 per share. The company expects to raise about $30 million from the offering.
Evofem was slipping 24.03% to $1.77.

 

Related Articles (BMY + APOP)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks Health Care Offerings Small Cap Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com